With proven performance in more than 20 peer-reviewed publications, Cxbladder is used by over 4,400 US urologists in more than 100,000 patients.
Multiple clinical trials have shown Cxbladder Monitor to be a highly accurate test for ruling out tumors. A study with data from over 1,100 US patient samples found that Cxbladder Monitor significantly outperforms current FDA-approved urine-based monitoring tests, including cytology and UroVysion FISH2.
Browse Our Clinical Publications
2 Lotan Y, OʼSullivan P, Raman JD, Shariat SF, Kavalieris L, Frampton C, et al. Clinical comparison of non-invasive urine tests for ruling out recurrent urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations. Elsevier; 2017;1–8.